Company Shares of Geron Corporation Drops by -1.44%

Geron Corporation (NASDAQ:GERN) has tumbled 1.44% during the past week and has dropped 3.19% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 0.26%. Geron Corporation (NASDAQ:GERN) has underperformed the index by 4.07% in the last 4 weeks. Investors should watch out for further signals and trade with caution.

Geron Corporation (NASDAQ:GERN): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $2.72 and $2.71 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $2.80. The buying momentum continued till the end and the stock did not give up its gains. It closed at $2.73, notching a gain of 1.11% for the day. The total traded volume was 4,496,555 . The stock had closed at $2.70 on the previous day.

The company shares have dropped -34.53% from its 1 Year high price. On Dec 2, 2015, the shares registered one year high at $5.30 and the one year low was seen on Feb 26, 2016. The 50-Day Moving Average price is $2.82 and the 200 Day Moving Average price is recorded at $3.26.

On the companys insider trading activities,The officer (EVP, Chief Financial Officer) of Geron Corp, Bloom Olivia Kyusuk sold 2,380 shares at $3.84 on May 29, 2015. The Insider selling transaction had a total value worth of $9,139. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Currently the company Insiders own 5.82% of Geron Corporation shares according to the proxy statements. Institutional Investors own 42.46% of Geron Corporation shares.

Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides a capacity for limitless, uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR), which binds to the telomere, and a catalytic subunit (hTERT) with reverse transcriptase activity, which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry, the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.

Leave a Reply

Charles Elwell - Is it time to Sell?

Top Brokerage Firms are advising their investors on Charles Elwell. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.